Microdosing 2026: What It Is, What Substances It Contains, Legality in Poland

Microdosing is one of the most searched terms in the field of mental health. According to the Global Drug Survey 2023 report, about 22% of respondents using psychedelics reported regular microdosing, and the market for "legal substitutes" for psychedelics, such as CBD, CBG, and functional mushrooms, exceeded $35 billion in 2024 (Global Drug Survey, 2023). In Poland, the topic raises interest and a lot of legal confusion.

This guide has one goal: to separate hype from evidence. We will show the definition of a subperceptual dose according to James Fadiman, the current state of clinical research from Johns Hopkins and Imperial College London, sharp differences between Fadiman's and Stamets' protocols, and the key Polish legal reality. Substances such as psilocybin, LSD, or DMT will be discussed solely in a scientific-informational context. The legal options for real microdosing practice in Poland remain CBD, CBG, and adaptogens.

The article is based on research published in eLife, Nature Medicine, Journal of Psychopharmacology, British Journal of Pharmacology, Frontiers in Pharmacology, and reports from EMCDDA and WHO. The author is Michał Waluk, editor of the u Bucha blog, who has been educating about cannabinoids since 2022. We do not provide medical advice and do not promote the use of controlled substances.

KEY INFORMATION
– Microdosing means taking 1/10 to 1/20 of a psychoactive dose, a threshold popularized by James Fadiman in the book "The Psychedelic Explorer's Guide" (2011).
– The largest self-blind RCT Szigeti 2021 (Imperial College, n=191) showed that the placebo group and the microdose group of psilocybin or LSD reported almost identical mood improvements, indicating a strong expectation component (eLife, 2021).
– Psilocybin, LSD, and DMT are illegal in Poland (the 2005 Drug Prevention Act, list I-P).
– Legal, scientifically justified microdosing options in Poland: CBD, CBG, Lion's Mane (Hericium erinaceus), Rhodiola rosea.
– CBD protocol: 2.5-5 mg of CBD 3-4 times a day in 5% or 10% broad spectrum oil, according to Project CBD recommendations.

What is microdosing and where did it come from?

Microdosing means regular, long-term intake of sub-perceptual doses of a psychoactive substance, typically from 1/10 to 1/20 of a dose that produces full effects. The term was popularized by American psychologist James Fadiman in the book "The Psychedelic Explorer's Guide" from 2011, based on research from the 1960s on "integrative doses" of LSD (Frontiers in Psychiatry, 2022).

The threshold principle is key. Fadiman argues that the microdose should be below the so-called perceptual threshold: a microdoser should not experience classic psychedelic effects (visual hallucinations, time distortion, euphoria). For psilocybin, this is 0.1-0.3 g of dried Psilocybe cubensis mushrooms, and for LSD, 10-20 micrograms. In comparison, a full recreational dose of psilocybin is 2-3.5 g, and for LSD, it is 100-200 micrograms.

Why specifically 1/10? Fadiman himself does not present pharmacokinetic data justifying this specific ratio. It is rather a practical heuristic based on his own observations and reports from hundreds of participants in his "microdosing reports" from 2010-2018. Researchers from Imperial College London showed that the perceptual threshold varies individually in the range of 5-25 micrograms of LSD (Trends in Cognitive Sciences, 2020).

How did it become mainstream?

The first wave of popularity emerged from Silicon Valley around 2015. Engineers and entrepreneurs described microdosing LSD as a "productivity hack." Journalist Ayelet Waldman published the book "A Really Good Day" in 2017, which was many people's first encounter with this topic. Since then, the movement has been growing. In 2024, the r/microdosing forum had over 280,000 registered users.

The second wave is the medical context. Research on full doses of psilocybin in depression (Johns Hopkins, Imperial College, Usona Institute) yielded results that attracted the attention of mainstream psychiatry. Some researchers began testing whether lower doses also produce effects. At the same time, a new branch emerged: "legal microdosing" with CBD, CBG, Lion's Mane, and Rhodiola as the main characters.

Is this a new trend or something old in a new package?

From an anthropological perspective, microdosing is not new. Indigenous cultures in Mexico and the Amazon have used low, regular doses of plant psychoactive extracts in ceremonial and work contexts for centuries. The Mazatecs from Oaxaca use Salvia divinorum, and in the Amazon, "dietas" with so-called teacher plants are practiced. The novelty is the medicalization and quantitative approach, not the practice itself.

What is also new is the strictly self-reported nature of the data. Most current conclusions about efficacy come from online surveys, observational studies, or open trials. RCTs are still few. This places microdosing in an uncomfortable position between folklore and pharmacology. Scientific rigor is only catching up with the enthusiasm of the user community.

Microdosing involves taking 1/10 to 1/20 of a psychoactive dose, a threshold popularized by James Fadiman (James Fadiman, 2011). For psilocybin, this is 0.1-0.3 g of dried mushrooms, and for LSD, 10-20 micrograms. Researchers from Imperial College London indicate that the perceptual threshold varies individually from 5-25 micrograms of LSD (Trends in Cognitive Sciences, 2020).

What substances can be microdosed and what does science say?

The scientific literature describes microdosing of several groups of substances, but their legal status and the quality of evidence vary drastically. According to the review by Polito and Liknaitzky 2022, the most frequently studied are psilocybin and LSD (78% of publications), followed by DMT, 2C-B, MDMA, ketamine, and cannabinoids (Frontiers in Psychiatry, 2022). In Poland, only non-psychoactive cannabinoids and adaptogens have legal status as options.

Let's take a look at the most important categories, starting with controlled substances in a scientific-informational context, and then moving on to what is realistically available and legal in Poland. Separating these two planes is fundamental here: information does not equal recommendation.

Psilocybin: what do Johns Hopkins and Imperial College show?

Psilocybin is a tryptamine alkaloid found in mushrooms of the genera Psilocybe, Panaeolus, and Gymnopilus. In the body, it is dephosphorylated to psilocin, which acts as a partial agonist of the 5-HT2A receptor in the cerebral cortex. Groundbreaking studies from 2020-2024 focus on full therapeutic doses, not microdoses. For example, Carhart-Harris 2021 showed in Nature Medicine that psilocybin does not yield to escitalopram in treatment-resistant depression (Nature Medicine, 2021).

Microdoses of psilocybin have been studied much less. An open study from Macquarie University (Prof. Vince Polito) showed a short-term mood improvement in 98 individuals, but without a control group. The interpretation is limited. The flagship rigorous study is Szigeti 2021: a self-blind online RCT where participants encapsulated their own substances along with placebo. The effect in the active and placebo groups was statistically indistinguishable (eLife, 2021).

In Poland, psilocybin is a controlled substance listed in category I-P of the Act of July 29, 2005, on drug addiction prevention. Possession, cultivation of psilocybin mushrooms, and trafficking are punishable. Psilocybe semilanceata mushrooms occur naturally in Polish meadows, but their collection and possession are as illegal as synthetic psilocybin. For the Polish reader, this substance remains a research topic, not a practical one.

LSD: microdosing and data from the University of Chicago

LSD (lysergic acid diethylamide) was discovered by Albert Hofmann in 1938. Active recreational doses are 50-200 micrograms, and microdoses are 10-20 micrograms. Harriet de Wit at the University of Chicago conducted several randomized, placebo-controlled trials with 13 and 26 micrograms of LSD. The results showed subtle changes in emotion processing and time perception, but no statistically significant mood changes (Journal of Psychopharmacology, 2020).

A separate topic is safety. LSD at high doses chronically shows affinity for the 5-HT2B receptor, which is present on heart valves. Long-term microdosing could theoretically cause valvulopathy similar to that observed with dopaminergic drugs like pergolide. The Rootman 2021 review indicates that there is currently a lack of long-term safety data beyond 12 months of practice (Journal of Psychopharmacology, 2021).

In Polish law, LSD is a substance listed in category I-P, the same law from 2005. Possession, trade, and production are punishable with penalties of up to 10 years of imprisonment depending on the amount. No legal "substitutes for LSD" from pharmacies or stores exist. Limited allowance in Poland applies only to clinical trials conducted by registered institutions licensed for psychoactive substances.

DMT, ketamine, MDMA: research context

DMT (dimethyltryptamine) is an endogenous alkaloid present in trace amounts in the brains of mammals. Research from Imperial College shows that continuous infusion of DMT can simulate an "expanded trip" in controlled conditions, which may be a future psychiatric tool. In Poland, DMT and ayahuasca are illegal as substances listed in category I-P.

Ketamine has a different status. As an NMDA dissociative anesthetic, it is medically registered, and the derivative esketamine (Spravato) has been approved in the EU for the treatment of treatment-resistant depression since 2019. Microdosing ketamine in sublingual tablet form is an emerging clinical field, studied by companies like Mindbloom and Innerwell. In Poland, ketamine remains a prescription drug within hospital procedures, and recreational microdosing is illegal.

MDMA is a substance listed in category I-P in Poland. Microdosing MDMA is being studied in the context of PTSD in conjunction with psychotherapy (MAPS studies in the USA). The FDA denied registration of MDMA for PTSD treatment in August 2024, citing insufficient data quality, despite promising results in Phase III. For the Polish practitioner, this remains a purely observational topic, not applicable.

Unique observation: In the discussion about microdosing psychedelics, two completely different things are confused. First, full doses of psychedelics given in clinical settings with psychotherapy – here the evidence is solid for treatment-resistant depression and PTSD. Second, the microdosing practice in the Silicon Valley style – here the evidence is weak and dominated by placebo. Mixing these two levels in the media creates a false impression that "microdosing cures depression," while RCTs show a marginal effect.

Does microdosing work, or is it just placebo?

This is the most important and controversial question in the field. The largest rigorous study to date, Szigeti 2021 from Imperial College London, included 191 individuals in a self-blind online RCT. Participants microdosing LSD or psilocybin placed their own substances in opaque capsules along with placebo, unaware of what they were taking on which day. The result: both groups reported nearly identical mood improvements (eLife, 2021).

This does not mean that the effects are illusory. It means that a very large part of the benefits comes from expectations, ritualization, and the so-called Hawthorne effect (the mere observation changes behavior). However, it is worth knowing that placebo is not synonymous with "worthless." The placebo effect in psychiatry often accounts for 30-50% of therapeutic response, which is a real clinical change, even if resulting from ritual.

What do open studies show? Rootman 2021 analyzed data from 8,500 users of the Quantified Citizen app. In the microdosing psilocybin group, mood improvement was observed, but also an increase in neuroticism. The same methodology without placebo does not allow separating the effect of the substance from participant selection and expectations. The conclusions are methodologically weak (Scientific Reports, 2021).

What does good evidence vs. weak evidence look like?

The hierarchy of evidence in medicine is as follows: multicenter RCT > single-center RCT > quasi-experimental study > observational study > case report. In microdosing, we have only two solid RCTs (Szigeti 2021 and de Wit 2020), a few quasi-experiments, and hundreds of self-reports. This is fuel for enthusiasm, but not for clinical recommendations.

What would need to happen for microdosing to be included in guidelines? Multicenter RCTs with an active comparator (e.g., SSRIs), a large sample size (n>300 per group), at least 12 weeks of follow-up, a primary endpoint on a clinically validated mood scale (e.g., HAM-D, MADRS), and replication in two independent laboratories. This is still lacking. The status as of 2026 remains one of exploration, not recommendation.

Conclusions for the Polish reader

Is it worth "trying"? The answer depends on which substance we are talking about. Microdosing psilocybin or LSD in Poland is a crime, and scientific evidence for their effects in microdoses is weak. Microdosing CBD, CBG, Lion’s Mane, and Rhodiola is legal, has better safety data, and may subjectively help, although partly due to the placebo effect.

In our conversations with clients, we often hear that the greatest value of the microdosing protocol lies not in the substance itself, but in the intentionality: the person starts keeping a mood journal, pays attention to sleep, regulates caffeine intake, and meditates. These "additions" have a stronger evidence base than the substance itself. This is a practical observation, not an excuse.

The self-blind RCT Szigeti 2021 (n=191, Imperial College London) showed that individuals microdosing LSD or psilocybin and those on placebo reported nearly identical mood improvements after 4 weeks (eLife, 2021). Conclusion: a large part of the reported effect of microdosing is due to expectations and ritualization, not the pharmacological action of the substance.

What are the microdosing protocols of Fadiman and Stamets?

The two most well-known microdosing protocols are Fadiman's scheme (2011) and Stamets Stack (2018). They differ in frequency, composition, and philosophy. The Kuypers 2019 review indicates that over 85% of individuals microdosing psychedelics use one of these two schemes or their variation (Frontiers in Psychiatry, 2019). Neither has formal RCT validation.

Protocols are practical frameworks, not dogmas. For legal microdosing of CBD and CBG in Poland, some principles can be drawn from them (day rotation, effect observation, journaling), but the detailed structure is different because the pharmacokinetics of CBD differs drastically from psilocybin or LSD.

Fadiman's protocol (1 day on 3)

The structure is simple: day 1 – microdose (1/10-1/20 of the psychoactive dose), day 2 – break, day 3 – break, day 4 – microdose, and so on. The cycle lasts 4 to 8 weeks. Fadiman argues that a regular break prevents the development of tolerance, which appears quickly at the 5-HT2A receptor with psilocybin and LSD, already after 2-3 days of subsequent dosing.

The goal of the protocol is the so-called "residual effect": a subtle improvement in mood the day after dosing, not on the day of intake. The person keeps a journal, noting 4 parameters: mood (1-10), concentration (1-10), creativity (1-10), sleep quality (1-10). After 4 weeks, there is a 2-week break. This allows observation of what changes without the substance.

Stamets' protocol (4 days on 3, stack with Lion’s Mane)

Paul Stamets, an American mycologist, proposed a combined scheme in 2018: psilocybin + Lion’s Mane (Hericium erinaceus) + vitamin B3 (niacin). Schedule: 4 days dosing, 3 days break. Stamets' hypothesis assumes neuroplastic synergy, where psilocybin increases BDNF, Lion’s Mane stimulates NGF synthesis through erinacines, and niacin facilitates distribution through skin flushing (Journal of Psychoactive Drugs, 2023).

This is a more speculative hypothesis than Fadiman's protocol. There are no RCTs confirming the synergy. The microdosing movement has picked up the idea due to its intuitive appeal: if two agents stimulating neuroplasticity are good, three are better. In Polish practice, where psilocybin is illegal, only two elements of the stack can be safely used: Lion’s Mane and niacin. This is the best bridge to a legal analogy.

Legal adaptation: CBD and CBG microdosing protocol

For the Polish reader, a practical adaptation looks like this. Instead of psilocybin, choose CBD or CBG. The scheme recommended by Project CBD is "split dosing": one larger evening dose is not optimal because the half-life of CBD is 18-32 hours, and a more stable level can be maintained by spreading out the doses. Protocol: 2.5-5 mg CBD 3-4 times a day, daily for 4 weeks, then 1 week break.

In practice, 1 drop of 5% CBD oil is about 2.5 mg of cannabidiol. Start with 1 drop in the morning, at noon, and in the evening. After 7 days, assess the effect (journal: mood, sleep, concentration). If there is no reaction – increase to 2 drops per dose. The maximum daily dose in the exploratory phase is 40 mg of CBD, which is about 16 drops of 5%. Above this, consult a doctor, especially if other medications are being taken.

Bucha data Q1 2026: In our store, 38% of customers asking about "microdosing" buy 5% broad spectrum CBD oil, 27% buy 10% CBD oil, 18% buy 15% CBG oil, and 12% buy CBD flowers for vaporization. 67% of customers reported that after 4-6 weeks they see "better sleep quality" or "less evening tension". This is a commercial observation, not a controlled clinical study, but it aligns with existing literature on CBD and CBG in the context of anxiety and sleep.

Fadiman's protocol assumes 1 day of microdosing and 2 days off, Stamets' protocol 4 days of dosing and 3 days off with the addition of Lion’s Mane and niacin (Journal of Psychoactive Drugs, 2023). Neither has formal RCT validation. For legal practice in Poland, "split dosing" of CBD is recommended: 2.5-5 mg 3-4 times a day, according to Project CBD recommendations.

What does science say about CBD microdosing?

CBD (cannabidiol) is a non-psychoactive cannabinoid derived from hemp. Unlike psilocybin and LSD, it has a solid evidence base in anxiety disorders, sleep disorders, and epilepsy. WHO assesses CBD as well-tolerated in doses up to 1500 mg per day without potential for addiction (WHO, 2018). In Poland, CBD from hemp containing less than 0.3% THC is legal and available without a prescription.

The concept of microdosing CBD differs from psychedelics. CBD does not induce a "full dose" with intoxicating effects. Microdosing CBD here rather means a strategy of fractional dosing, where the goal is to maintain a stable therapeutic level with the minimum effective amount. The analogy to psilocybin is loose, but the philosophy of regularity and intentionality is the same.

Pharmacology of CBD and why split-dose makes sense

CBD has sublingual bioavailability of 13-19% and a half-life in plasma of 18-32 hours (PMC, Frontiers in Pharmacology, 2020). It acts on multiple fronts: as a negative allosteric modulator of CB1, a partial agonist of 5-HT1A, a TRPV1 activator, and an FAAH inhibitor (the enzyme that breaks down anandamide). The 5-HT1A mechanism is key for anxiolytic effects.

Why split-dose? A single large dose of 50 mg in the evening peaks in concentration about 1-3 hours after intake, then gradually decreases. Spreading it out to 4 x 12.5 mg provides a more stable serum level throughout the day. Subjectively, this means less mood and tension fluctuations, a more "smooth background". In the Zuardi 2017 study, volunteers with social phobia experienced comparable anxiolytic effects from 300 mg taken at once and 3 x 100 mg throughout the day (PMC, Frontiers in Pharmacology, 2017).

For whom is CBD microdosing suitable?

The best-documented indications are: chronic anxiety (Shannon 2019, n=72, 79% improvement with 25-75 mg daily), sleep disorders (Stueber 2024, 48-66% improvement in sleep quality), chronic non-inflammatory pain (Cochrane review 2023 – mixed data), chronic muscle tension. CBD does not treat clinical depression but can support comorbid anxiety symptoms (Frontiers in Psychiatry, 2024).

Who should not experiment without consultation? Pregnant and breastfeeding women, individuals with severe liver failure, patients on warfarin, valproate, clobazam, and other drugs metabolized by CYP2C9/CYP3A4. Individuals with bipolar disorder should be cautious due to rare reports of mania triggering. Always, I repeat, always consult with the attending physician.

Which CBD oil to choose for microdosing?

For beginners, we recommend broad spectrum 5%. 1 drop is about 2.5 mg of CBD, 1 ml is about 50 mg. With a dose of 4 x 2.5 mg daily, a 10 ml bottle lasts about 50 days. For more experienced users, 10% is more convenient, as 1 drop is about 5 mg. Important criteria: certificate of analysis (COA), no THC or below 0.3%, MCT carrier or olive oil, known manufacturer from the EU.

SOOL Broad Spectrum CBD Oil 5% in 10 ml is a realistic starting option for 76 PLN. For those seeking higher potency, there is SOOL Broad Spectrum CBD Oil 10% for 99 PLN, where one drop provides about 5 mg of cannabidiol and allows for maintaining doses of 15-20 mg daily with a smaller volume. The choice depends on the goal, weight, and tolerance.

CBD is well tolerated in doses up to 1500 mg daily, with sublingual bioavailability of 13-19%, and a half-life of 18-32 hours (WHO, 2018; Frontiers in Pharmacology, 2020). Microdosing CBD in a split-dose protocol is 2.5-5 mg 3-4 times a day. For beginners, 5% broad spectrum oil, for experienced users, 10%. Always consult a doctor when taking medications.

Why is CBG an intriguing microdosing option?

CBG (cannabigerol) is known as the "parent cannabinoid" from which CBD, THC, and CBC are enzymatically derived. In the fresh cannabis plant, it occurs in small amounts, usually 0.1-1%, which is why CBG oils are more expensive than CBD. The Calapai 2022 review in the British Journal of Pharmacology indicates neuroprotective, anti-inflammatory, and GABAergic actions of CBG in preclinical studies (British Journal of Pharmacology, 2022).

CBG acts differently than CBD. The main molecular targets are alpha-2 adrenergic receptors (which modulate attention and arousal, similar to clonidine), 5-HT1A, and PPAR-gamma. Some users describe CBG as "more stimulating during the day, less calming in the evening". This distinguishes it from CBD, which has a more relaxing profile. For those who do not want drowsiness from CBD, CBG can be a better daytime choice.

What is the evidence for CBG's effects?

Most evidence comes from preclinical studies in vitro and animal models. Valdeolivas 2015 showed the neuroprotective effect of CBG in a Huntington's disease model in mice, Borrelli 2014 showed anti-inflammatory effects in a model of inflammatory bowel disease. There are few clinical studies in humans. A pilot study by Cuttler 2024 with n=127 showed subjective improvement in anxiety and concentration in individuals taking 20-40 mg of CBG daily, without a control group (Psychopharmacology, 2024).

It still has a weaker evidence base than CBD. An important note: CBG is regulated in the same category as CBD in Poland – legal if the THC content in the product is below 0.3%. The safety profile is similar to CBD, with no potential for addiction and no psychoactive effect. For those who do not like the sedative effect of CBD, CBG can be a practical alternative.

The practice of CBG microdosing

A typical CBG microdose is 2.5-5 mg 2-3 times a day. This means a total of 5-15 mg of CBG daily, significantly less than the typical dose of CBD (20-50 mg). Why less? CBG seems to have higher receptor-level efficacy in certain pathways, so low doses are sufficient. Pharmacokinetic data are less precise than for CBD, so this is an empirical heuristic, not pharmacodynamics from RCT.

In practice, we recommend Cannova CBG Oil 15% for individuals experimenting with microdosing. 1500 mg of CBG in 10 ml means about 7.5 mg of CBG per drop, making precise dosing convenient. The price of 240 PLN is higher than CBD, but a daily dose of 5-10 mg provides a bottle for about 60-90 days. Protocol: 1 drop in the morning + 1 drop in the early afternoon for the first 2 weeks, then possible increase.

CBG acts on alpha-2 adrenergic receptors, 5-HT1A, and PPAR-gamma, showing neuroprotective and anti-inflammatory effects in preclinical studies (British Journal of Pharmacology, 2022). A typical microdose is 2.5-5 mg of CBG 2-3 times a day, with 15% oil providing about 7.5 mg per drop. CBG is legal in Poland and does not show potential for addiction.

How do adaptogens fare: Lion’s Mane and Rhodiola?

Adaptogens are a separate category. They are not psychedelics, but have entered the microdosing ecosystem as "natural, legal cognitive enhancers". Lion’s Mane (Hericium erinaceus) and Rhodiola rosea are the most researched representatives. The Hymanson 2024 review in Phytomedicine indicates that Lion’s Mane in doses of 500-1000 mg daily stimulates NGF and BDNF synthesis, while Rhodiola 200-600 mg reduces mental fatigue (Phytomedicine, 2023).

In Poland, both are legal as dietary supplements. They are not medications and cannot be advertised for therapeutic purposes. However, this is the easiest available category of "neurosupport" for someone who wants to experiment with safe substances without legal risk.

Lion’s Mane: NGF, BDNF, and the cerebral cortex

Lion’s Mane contains erinacines and hericenones, compounds that in vitro stimulate NGF (nerve growth factor) and BDNF (brain-derived neurotrophic factor) synthesis. In the Mori 2009 study involving older adults with mild cognitive impairment, 4-week supplementation of Lion’s Mane at 3 x 250 mg improved scores on the HDS-R test (Phytotherapy Research, 2009). The effect faded after discontinuation.

Contemporary studies are limited but consistent in their signal. Li 2020 indicated that erinacines cross the blood-brain barrier and stimulate neurogenesis in the hippocampus in mice. For humans, this means a theoretical potential to support memory and learning. Do not expect a "lifestyle hack" effect in 3 days, rather after 4-8 weeks of supplementation at 500-1000 mg daily.

Rhodiola rosea: salidroside and mental fatigue

Rhodiola (rose root) contains salidroside and rosavins, which modulate HPA axis pathways (hypothalamic-pituitary-adrenal axis). The Ishaque 2012 review indicates improved resistance to mental stress and reduced feelings of fatigue in individuals with moderate exhaustion (BMC Complementary Medicine and Therapies, 2012). The standard dose is 200-600 mg of 3% salidroside extract daily, preferably in the morning.

Rhodiola does not work like caffeine: the effect is subtler and develops over 2-3 weeks. The main contraindication is bipolar disorder (Rhodiola may theoretically enhance activation in susceptible individuals). Individuals on MAOIs and SSRIs should consult with a doctor, although interactions are rare and mild.

How to arrange an adaptogen stack consistent with Stamets Stack?

For individuals in Poland, a safe adaptation of the Stamets Stack looks like this. Element 1: Lion’s Mane 500-1000 mg daily in capsules or powder in the morning. Element 2: Rhodiola rosea 200-400 mg daily in the morning (along with coffee, if tolerated). Element 3: Niacinamide 100-500 mg (a milder form than niacin, without flushing), but not for individuals with hyperhomocysteinemia.

Element 4 is a legal substitute for psilocybin: 15% CBG oil 5-10 mg in the morning or 5% CBD oil 5-10 mg in the morning. Schedule 4 days on, 3 days off, in 4-6 week cycles with a week off. This is not "therapy", it is a personal experiment with a qualitative journal of mood, sleep, and concentration. It does not replace psychiatric treatment for clinical depression or generalized anxiety.

Lion’s Mane 500-1000 mg daily stimulates NGF and BDNF synthesis, Rhodiola rosea 200-600 mg reduces mental fatigue (Phytomedicine, 2023). Both are legal in Poland as supplements. The best application: an adaptogen stack with CBD or CBG instead of psilocybin, 4 days on / 3 days off, with a journal of subjective parameters.

What is the legality of microdosing in Poland?

Poland has strict laws regarding psychoactive substances. The Drug Addiction Prevention Act of July 29, 2005 (Journal of Laws 2005 No. 179 item 1485) categorizes psilocybin, LSD, DMT, MDMA, and other psychedelics in lists I-P (psychotropic substances of group I). Their possession, cultivation, trafficking, and production are punishable (Journal of Laws 2005 No. 179 item 1485).

Penalties are severe. Article 62 of the law: possession of a small amount of a psychotropic substance – fine, restriction, or imprisonment for up to 3 years. Possession of a "significant amount" – up to 10 years. Cultivation of psilocybin mushrooms (Article 63) – up to 8 years. Trafficking (Article 56) – up to 12 years. For the Polish reader, this clearly means: microdosing psilocybin or LSD in Poland is a crime, even with "therapeutic" intent.

What is legal?

The list of legal substances for microdosing in Poland is short but practical. First: CBD derived from hemp with THC content below 0.3%. Second: CBG under the same regulatory regime. Third: adaptogens – Lion’s Mane, Rhodiola rosea, Ashwagandha (Withania somnifera), Bacopa monnieri – all in the status of dietary supplements. Fourth: coffee and L-theanine as classic "soft nootropics".

Medical marijuana (Bedrocan, Tilray, etc.) with THC is legal in Poland only by prescription. Including it in microdosing is technically possible – low oral doses of 1-2.5 mg THC are clinically used in palliative oncology and chronic pain. However, "microdosing marijuana" without a prescription outside the system is illegal, and medical use requires the competence of an oncologist or neurologist, not a self-made decision.

Will Polish law change?

Short answer: it's hard to predict. Long answer: we are observing movements at the European level and in selected countries (Germany, Czech Republic), where discussions about the decriminalization of certain psychedelics in a therapeutic context are increasing. Australia has allowed psilocybin for the treatment of resistant depression under psychiatric supervision since 2023, and the FDA in the USA considered psilocybin's status as a "breakthrough therapy" in 2022.

In Poland, public discussion is at an early stage. There are no government pilot programs. Realistically, in a horizon of 3-5 years, changes are unlikely. The most sensible strategy for the Polish reader interested in microdosing: focus on legal options (CBD, CBG, adaptogens) and follow clinical research on full doses of psychedelics from an informational perspective.

The Drug Addiction Prevention Act of July 29, 2005, classifies psilocybin, LSD, DMT, and MDMA in list I-P, with penalties of up to 10 years of imprisonment for possession (Journal of Laws 2005 No. 179 item 1485). Legal for microdosing in Poland are: CBD, CBG, Lion’s Mane, Rhodiola rosea, Ashwagandha, Bacopa monnieri. Medical marijuana requires a doctor's prescription.

What are the risks and contraindications of microdosing?

Risks vary drastically between substances. For psilocybin, LSD, and DMT, the main risk in Poland is legal: penalties of up to 10 years of imprisonment. For CBD, CBG, and adaptogens, the risk is pharmacological, usually mild. WHO assesses CBD as safe, but 6-14% of patients in the Epidiolex registry experience clinically significant adverse effects (WHO, 2018).

The most important risk groups for any type of microdosing are: pregnant and breastfeeding women, individuals with a predisposition to psychosis (personal or family history of schizophrenia), individuals with severe liver or heart disease, patients on multiple liver-metabolized medications. Never experiment without consultation if you belong to any of these groups.

Risks of microdosing psychedelics (informational)

First: cardiotoxicity. LSD and 2C-B have affinity for 5-HT2B, a receptor on heart valves. Long-term microdosing could theoretically induce valvulopathy, similar to dopaminergic drugs. Second: triggering psychosis in susceptible individuals. Here, particular attention is required for individuals with a family history of schizophrenia or bipolar disorder (Journal of Psychopharmacology, 2020).

Third: interactions with psychiatric medications. SSRIs and MAOIs can unpredictably amplify or weaken the effects of psilocybin and LSD. Lithium with psilocybin could theoretically increase the risk of seizures. Fourth: tolerance and ritual. Microdosing 5-7 days a week quickly builds tolerance to 5-HT2A. Without "reset days," the effect fades.

Risks of microdosing CBD and CBG

CBD is well tolerated. The most common side effects are: dry mouth (11%), drowsiness (8%), dizziness (5%), diarrhea (4%), fatigue (3%). An increase in liver enzymes occurs at doses >300 mg per day or with concurrent use of valproate. For micro doses (10-40 mg), the risk of hepatotoxicity is negligible. Potential for addiction – none.

Drug interactions are significant. CBD inhibits CYP2C9, CYP2C19, CYP3A4, and CYP2D6 enzymes. Medications of particular concern: warfarin, valproate, clobazam, SSRIs, tramadol. A 2023 review identified 139 drugs with potentially clinically significant interactions with CBD (Medical Cannabis and Cannabinoids, 2023). Space out dosing by 2-4 hours and always inform your attending physician.

When should you not start microdosing?

Never as a substitute for psychiatric treatment in depression, generalized anxiety, PTSD, bipolar disorder, schizophrenia. Microdosing even legal substances does not replace cognitive-behavioral therapy (CBT), exposure (for phobias), SSRIs/SNRIs in depression, or lithium in bipolar disorder. These are tools with a solid evidence base.

Also be cautious with: unstable heart disease (AF, heart failure), severe liver failure (Child-Pugh C), untreated epilepsy, active addiction to alcohol or other substances. For these patients, experiments with microdosing without medical supervision can be dangerous. Always talk to a psychiatrist or neurologist before starting.

The main risks of microdosing psychedelics are cardiotoxicity 5-HT2B (valvulopathy of heart valves), triggering psychosis in susceptible individuals, and criminal liability in Poland (Journal of Psychopharmacology, 2020). CBD has a good safety profile but has 139 potential drug interactions (Medical Cannabis and Cannabinoids, 2023). Never replace psychotherapy or pharmacotherapy.

How to assess the quality of CBD or CBG oil for microdosing?

Product quality determines safety and effect. A 2021 U.S. FDA report indicates that in market samples of CBD oils, 43% had declared CBD content that was either under or overestimated by >10%, and 21% contained unacceptable levels of contaminants (pesticides, heavy metals, solvents) (FDA, 2021). In Europe, the situation is better due to Novel Food regulation, but quality still varies.

Five criteria for a reliable assessment are as follows. First: a certificate of analysis (COA) for each batch, available online, from an independent laboratory, with results for CBD, THC, and contaminants. Second: source of hemp – the EU has stricter regulations than imports from outside the EU. Third: extraction method – supercritical CO2 is the gold standard, ethanol extraction is acceptable, solvent extraction is risky.

What to pay attention to when evaluating a product?

Fourth: the manufacturer – a company with an address, KRS/NIP number, user reviews, and a market history of >2 years. Fifth: price – too cheap is suspicious. A realistic price for 5% broad spectrum CBD oil 10 ml is 70-120 PLN, for 10% oil 100-180 PLN. Dramatically lower prices usually indicate a diluted product or isolate marketed as broad spectrum. CBD hemp flower typically costs 30-80 PLN for 1-2 grams.

For those preferring vaporization, there is Mars CBD 9% flower from the Konopny Buch brand for 59 PLN. The CBD content of 9% provides about 90 mg of CBD in 1 gram of flower, which, when vaporized with a bioavailability of 30-40%, gives an effective 27-36 mg of absorbed CBD from a gram. Vaporization has a quick onset of action (5-10 minutes) but is harder to dose precisely than oil.

Broad spectrum vs full spectrum vs isolate.

Broad spectrum contains CBD + other minor cannabinoids (CBG, CBN, CBC) + terpenes, but without THC. This is the best compromise for those who want the "entourage effect" without the risk of THC detection in a drug test. Full spectrum contains everything, including up to 0.3% THC. Isolate is pure, crystallized CBD, without other cannabinoids and terpenes – the purest form, but without entourage.

For microdosing, we recommend broad spectrum. Terpenes (beta-caryophyllene, linalool, myrcene) may enhance the anxiolytic and sedative effects of CBD. Minor cannabinoids (CBG, CBN, CBC) have additional neuroprotective and anti-inflammatory effects. Isolate works well if you want to limit exposure to just CBD, e.g., in scientific tests or at the beginning with uncertain tolerance.

43% of tested CBD products in the USA had declared CBD content that was either under or overestimated by >10%, and 21% contained unacceptable contaminants (FDA, 2021). Criteria for good quality: COA from an independent laboratory, CO2 extraction, manufacturer from the EU, history >2 years, realistic price (70-180 PLN/10 ml). For microdosing, the best is broad spectrum.

How to arrange an 8-week CBD microdosing protocol step by step?

I provide a practical framework that combines Fadiman's philosophy with CBD pharmacology. The protocol does not replace medical advice and is a personal experiment with a qualitative journal. Recommended for individuals without serious illnesses who want to explore the impact of low doses of CBD on their sleep, tension, and concentration. The basis: 5% broad spectrum CBD oil.

The key is intentionality. Do not start if you are stressed, sleeping <5 hours, or undergoing significant life changes. Do not mix with alcohol, new medications, or dietary changes. The isolated variable is CBD; if you add 5 other things, you won't know what works.

Weeks 1-2: baseline and start

For the first week, take nothing, keep a journal: mood (1-10), concentration (1-10), sleep quality (1-10), stress level (1-10), energy (1-10). Every evening before bed. This is your baseline. In the second week, start with 1 drop of 5% CBD oil (2.5 mg) 3 times a day: 8:00, 13:00, 20:00. Do not change coffee, exercise, or diet.

Sublingual application: drop under the tongue, hold for 60-90 seconds, swallow. Bioavailability is then 13-19%. Swallowing immediately reduces bioavailability to 6-8% and prolongs onset time. Keep the journal the same as in the baseline week. After 14 days, you have 2 weeks of observation: 7 days without and 7 days with a low dose of CBD.

Weeks 3-4: increase and observe

If you see no change in week 2, increase to 2 drops (5 mg) 3 times a day. The total daily dose will then be 15 mg of CBD. Maintain this dose for 2 weeks. For most people, this is the "trial" level – if you are a responder, the effect (improvement in sleep, less tension) will appear in weeks 3-4. If you see nothing after 4 weeks, increase to 3 drops (7.5 mg) 3 times a day.

Watch out for morning drowsiness. If a morning dose of 5 mg causes drowsiness, move it to 10:00 or reduce to 1 drop. Very individual. For some, 5 mg in the morning supports focus, for others, sedation. Trust the journal, not expectations. At this stage, you are already starting to distinguish what you subjectively feel from what is actually changing in the parameters.

Weeks 5-8: assessment, plateau, conclusion

In weeks 5-6, maintain a steady dose, observe. If the effect is solid (>1 point improvement in at least 2 diary parameters), maintain it. If not, change the strategy: timing of the dose, type of oil, maybe consider CBG instead of CBD. In weeks 7-8, start "tapering": reduce by 1 drop weekly to zero. The next 7-14 days without CBD is a "wash-out", observe what returns.

If symptoms return after the wash-out (poor sleep, tension), you have subjective evidence that CBD "works" for you. This is not placebo; it is information. In such a case, you can plan a return to the maintenance dose, preferably consulting with your attending physician. If nothing has changed after discontinuation, your effect was likely largely placebo. Still valuable information.

Our observations at u Bucha: Customers who keep an 8-week diary report a specific effect (improvement in sleep, less tension) significantly more often than those who take CBD "on feel." About 40% of responders see a reaction in weeks 2-3, another 30% in weeks 4-6, and 30% do not respond clinically significantly. Lack of response does not mean "bad batch of CBD" – it means that in some individuals, endocannabinoid receptors may react differently.

The 8-week CBD microdosing protocol is based on sublingual bioavailability of 13-19% and a half-life of 18-32 hours (Frontiers in Pharmacology, 2020). Start with 2.5 mg 3 times a day, increasing every 2 weeks, with a maximum of 40 mg daily in the exploratory phase. A mood, sleep, and concentration journal is key to distinguishing pharmacological effects from placebo.

Who should not microdose CBD or CBG?

Despite the good safety profile, CBD and CBG are not for everyone. In the Epidiolex registry, 6-14% of patients experience clinically significant adverse effects, mainly at doses >300 mg per day, but some groups should completely avoid supplementation without medical supervision (WHO, 2018). For microdoses (10-40 mg), the risk is lower but not zero.

The most sensitive groups are: pregnant and breastfeeding women, children and adolescents under 18 (developing brain), individuals with bipolar disorder, patients with severe liver failure, individuals on warfarin or valproate, organ transplant patients (CBD affects the metabolism of tacrolimus). For these groups, the recommendation is clear: consult with the attending physician before any experiment.

Pregnancy, breastfeeding, and microdosing

The American College of Obstetricians and Gynecologists (ACOG) recommends completely avoiding cannabinoids during pregnancy and while breastfeeding. THC crosses the placenta and enters breast milk, and data on CBD in this context is scarce but suggestive. Animal studies show an impact on the development of the fetal endocannabinoid system, which may have neurological consequences in the long term.

For women planning pregnancy, a cautious interval is also recommended. It is best to stop CBD/CBG 2-3 months before planned conception. For breastfeeding mothers: the same, complete avoidance. Alternatives for reducing anxiety during this period include psychotherapy, relaxation techniques, regular sleep, physical exercise, and a Mediterranean diet. Pharmacotherapy, if necessary, after consultation with the attending physician.

Interactions with psychiatric medications

CBD inhibits CYP2D6 and CYP2C19 enzymes, affecting the metabolism of SSRIs (fluoxetine, paroxetine, sertraline). Theoretically, this could increase the concentration of SSRIs in plasma and the risk of adverse effects. In practice, the effect at microdoses (10-40 mg of CBD) is usually clinically insignificant but individual. Monitoring the intensity of SSRI effects in the first 4 weeks of combination is recommended.

Drugs with a narrow therapeutic window require greater caution: warfarin (CBD inhibits CYP2C9, raises INR), valproate (combined hepatotoxicity), clobazam (increased concentration by 40-60%), tramadol (rare serotonin syndrome). MAOIs: no direct studies, but theoretical risk exists. Lithium: safe with CBD, but do not combine with high doses of THC or psychedelics.

Children and youth

For children, CBD is registered only for resistant epilepsy (Epidiolex, from age 2). For other indications, including microdosing for "concentration" or "anxiety," there is a lack of RCT. The AAP (American Academy of Pediatrics) strongly advises against CBD in children without strict specialist supervision. A child's and adolescent's brain develops intensively until age 25, especially the prefrontal cortex, and modulation of the endocannabinoid system may have long-term consequences.

Teenagers 16+ are a clinical gray area. Some experiment with CBD on their own. In such a situation, open conversation with parents and a doctor is key. Hiding use is more dangerous than controlled trials under supervision. Doses in teenagers considered medically are 10-20 mg of CBD daily, for a short period of 4-6 weeks, with strict monitoring. It does not replace standard psychiatric treatment.

Microdosing CBD and CBG is contraindicated during pregnancy, breastfeeding, and in children without specialist supervision. Interactions with warfarin, valproate, clobazam, and SSRIs require medical consultation (Medical Cannabis and Cannabinoids, 2023). In the Epidiolex registry, 6-14% of patients experience clinically significant adverse effects at high doses.

Summary: how to approach microdosing sensibly in 2026?

The conclusions are consistent but nuanced. First, microdosing psychedelics (psilocybin, LSD, DMT) is illegal in Poland, has weak clinical evidence (the strongest RCT Szigeti 2021 showed a dominant placebo effect), and carries legal and theoretical cardiological risks. For the Polish reader, this is an informational-research area, not applicable.

Secondly, legal options in Poland, CBD, CBG, Lion’s Mane, Rhodiola, have a more solid safety profile and reasonable pharmacological basis. CBD has the largest evidence base in anxiety and sleep disorders. CBG is promising as a lighter daily alternative. Lion’s Mane and Rhodiola are adaptogens with moderate evidence base but practical value.

Thirdly, the placebo effect is real and often outweighs the pharmacological effect. Mood diary, regularity, ritual, intentionality – these "soft" elements can have a greater impact on well-being than the substance itself. Microdosing as a "productivity hack" often disappoints. Microdosing as a structure of discipline in mental health can bring value.

Practical path: if you want to try, start with an 8-week protocol using 5% broad spectrum CBD oil, 2.5-5 mg 3 times a day, with a daily diary. After 8 weeks, assess what has changed. If the effect is insufficient, consider switching to 15% CBG or adding Lion’s Mane and Rhodiola. Always in the context of medical consultation if you have chronic diseases or are taking medications.

Key is realistic expectation. Microdosing is not a magic pill for depression, anxiety, or attention deficit. It is a potential supportive tool in conjunction with sleep, movement, diet, psychotherapy, and pharmacotherapy, if indicated. Those looking for a "quick alternative" will likely be disappointed. Those seeking a tool for long-term self-work may find valuable support in legal microdosing.

Frequently Asked Questions

What is microdosing?

Microdosing (microdosing) is the regular intake of subperceptual doses of a psychoactive or adaptogenic substance, typically 1/10 to 1/20 of a dose that induces full effects. The threshold popularized by James Fadiman in 2011 states that a microdoser should not experience classic psychedelic effects (Frontiers in Psychiatry, 2022). The declared goal of users is subtle improvement in mood, concentration, and creativity.

Is microdosing psilocybin and LSD legal in Poland?

No. Psilocybin, LSD, and DMT are classified as psychotropic substances in Poland under the Drug Addiction Prevention Act of July 29, 2005 (Journal of Laws 2005 No. 179 item 1485). Their possession, cultivation of psilocybin mushrooms, and trade are punishable. Legal microdosing in Poland is limited to uncontrolled substances such as CBD, CBG, and adaptogens like Lion’s Mane and Rhodiola rosea.

Does microdosing work, or is it just placebo?

The largest self-blind study in the world (Szigeti 2021, Imperial College London, n=191) showed that individuals on placebo and those on actual microdoses of LSD or psilocybin reported nearly identical mood improvements after 4 weeks, suggesting a dominant component of expectations (eLife, 2021). This does not mean that the effect does not exist; it means that it is largely psychological and dependent on ritual.

What is CBD microdosing and how to start?

CBD microdosing involves taking 2.5 to 5 mg of cannabidiol 3 to 4 times a day instead of one larger evening dose. The method recommended by Project CBD allows for maintaining a stable level of CBD in serum with sublingual bioavailability of 13-19% and a half-life of 18-32 hours (Frontiers in Pharmacology, 2020). Start with 5% broad spectrum oil and 1 drop 3 times a day for 7 days.

What is the difference between Fadiman's and Stamets' protocols?

The Fadiman protocol involves taking a microdose every third day (day 1 dose, days 2-3 break), for 4-8 weeks. The Paul Stamets protocol (Stamets Stack) combines psilocybin, Lion’s Mane, and vitamin B3 (niacin) according to a scheme of 4 days dose and 3 days break. Stamets postulates a neuroplastic synergy between psilocybin and erinacines from Lion’s Mane, but there is a lack of RCT confirming this hypothesis (Journal of Psychoactive Drugs, 2023).

Is Lion's Mane and Rhodiola microdosing?

In a strict definition, no, because these substances are not psychoactive at higher doses. In practice, users employ them as a legal, nootropic equivalent of microdosing. The Hymanson review 2024 indicates that Lion's Mane at doses of 500-1000 mg daily stimulates the synthesis of NGF and BDNF, while Rhodiola rosea at 200-600 mg reduces mental fatigue (Phytomedicine, 2023). Both supplements are legal in Poland.

Can CBG be microdosed?

Yes. CBG (cannabigerol) is a non-psychoactive cannabinoid, legal in Poland, and a good candidate for a microdosing protocol. A typical microdose is 2.5-5 mg of CBG 2-3 times a day. CBG acts on alpha-2 adrenergic receptors and 5-HT1A, and in preclinical studies, it shows neuroprotective and anti-inflammatory effects (British Journal of Pharmacology, 2022). A 15% oil provides a convenient drop worth about 7.5 mg of CBG.

What are the risks of microdosing?

The main risks are: criminal liability with psilocybin, LSD, and DMT in Poland, interactions with psychiatric medications (SSRIs, MAOIs, lithium), cardiotoxicity of LSD with long-term use due to valvulopathy (Journal of Psychopharmacology, 2020), and for individuals predisposed to psychosis, the risk of triggering it. Microdosing CBD and CBG has a significantly more favorable profile: no addiction potential, WHO assesses CBD as safe.

This article is informational and educational in nature and does not constitute medical advice. It does not promote or encourage the use of legally controlled substances in Poland. Psilocybin, LSD, DMT, and MDMA are illegal in Poland according to the Act on Counteracting Drug Addiction of July 29, 2005 (Journal of Laws 2005 No. 179 item 1485), and their possession, cultivation, and trade are punishable. Microdosing of CBD, CBG, and adaptogens (Lion's Mane, Rhodiola) is legal, but it does not replace psychiatric treatment for depression, anxiety disorders, PTSD, or other conditions requiring diagnosis and therapy. Before starting to use cannabis or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 23, 2026
Last update: April 23, 2026